Emily Menendez

Emily Menendez is the associate editor of GU Oncology Now and GI Oncology Now. She uses her copywriting experience to contribute content on the latest updates in the GU and GI oncology spheres. Ms. Menendez received her BA from the University of Central Florida.

Articles by Emily Menendez

Emily MenendezCRPC | May 6, 2025
Radium 223 is recommended for patients with symptomatic bone-only disease.
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | April 27, 2025
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Emily MenendezmCSPC | April 27, 2025
Patients with ARPI-treated mCSPC and BRCA1/2 alterations experienced higher rates of disease progression.
Emily MenendezUrothelial Carcinoma | April 27, 2025
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
Emily MenendezMuscle Invasive Urothelial Carcinoma | April 26, 2025
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Emily MenendezLocalized | April 26, 2025
Hemi-gland cryoablation and HIFU provided acceptable and eminent functional outcomes in patients over a 5-year follow-up.
Emily MenendeznccRCC | April 26, 2025
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
Emily MenendeznccRCC | April 16, 2025
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Emily MenendezLocalized | April 14, 2025
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Emily MenendezmHSPC | April 3, 2025
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
Emily MenendezMuscle Invasive Urothelial Carcinoma | April 2, 2025
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
Emily MenendezCRPC | March 31, 2025
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Emily MenendezUpper Tract Urothelial Carcinoma | March 26, 2025
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
Emily MenendezUrothelial Carcinoma Diagnostics | March 20, 2025
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
Emily MenendezProstate Cancer Diagnostics | March 13, 2025
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Emily MenendezRLT | March 7, 2025
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Emily MenendezAdvanced Urothelial Carcinoma | March 4, 2025
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
Emily MenendezUrothelial Carcinoma Diagnostics | February 28, 2025
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.